<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26623425</article-id><article-id pub-id-type="pmc">4662545</article-id><article-id pub-id-type="publisher-id">1</article-id><article-id pub-id-type="doi">10.1186/s41038-015-0001-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pathological conditions re-shape physiological Tregs into pathological Tregs</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>William Y</given-names></name><address><email>frankinxf_yang@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shao</surname><given-names>Ying</given-names></name><address><email>tuf43098@temple.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Pastrana</surname><given-names>Jahaira</given-names></name><address><email>tue55340@temple.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mai</surname><given-names>Jietang</given-names></name><address><email>mai263@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hong</given-names></name><address><email>hongw@temple.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Xiao-feng</given-names></name><address><email>xfyang@temple.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Centers for Metabolic Disease Research, Cardiovascular Research, and Thrombosis Research, Department of Pharmacology, Temple University School of Medicine, MERB 1059, 3500 North Broad Street, Philadelphia, PA 19140 USA </aff><aff id="Aff2"><label>2</label>Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140 USA </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>3</volume><elocation-id>1</elocation-id><history><date date-type="received"><day>16</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>2</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells (Tregs) are a subset of CD4 T cells that play an essential role in maintaining peripheral immune tolerance, controlling acute and chronic inflammation, allergy, autoimmune diseases, and anti-cancer immune responses. Over the past 20 years, a significant progress has been made since Tregs were first characterized in 1995. Many concepts and principles regarding Tregs generation, phenotypic features, subsets (tTregs, pTregs, iTregs, and iTreg35), tissue specificity (central Tregs, effector Tregs, and tissue resident Tregs), homeostasis (highly dynamic and apoptotic), regulation of Tregs by receptors for PAMPs and DAMPs, Treg plasticity (re-differentiation to other CD4 T helper cell subsets, Th1, Th2, Tfh, and Th17), and epigenetic regulation of Tregs phenotypes and functions have been innovated. In this concise review, we want to briefly analyze these eight new progresses in the study of Tregs. We have also proposed for the first time a novel concept that &#x0201c;physiological Tregs&#x0201d; have been re-shaped into &#x0201c;pathological Tregs&#x0201d; in various pathological environments. Continuing of the improvement in our understanding on this important cellular component about the immune tolerance and immune suppression would lead to the future development of novel therapeutics approaches for acute and chronic inflammatory diseases, allergy, allogeneic transplantation-related immunity, sepsis, autoimmune diseases, and cancers.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Regulatory T cells</kwd><kwd>Immune suppression</kwd><kwd>Epigenetic mechanisms</kwd><kwd>Histone modifications</kwd><kwd>Metabolic cardiovascular diseases</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells are classified as a subpopulation of CD4 T cells specialized in the suppression of immunopathogenic responses from the host immune system against self or foreign antigens and dangerous substances [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. The suppressive function of Tregs in the maintenance of self-tolerance and prevention of the development of autoimmune and chronic inflammatory diseases is mediated by different mechanisms such as Tregs killing of target cells [<xref ref-type="bibr" rid="CR3">3</xref>], modulation of target cell signaling via cell-cell contact and/or secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10), IL-35 [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>], and transforming growth factor &#x003b2; (TGF-&#x003b2;) [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref>] as well as modulation of target cells by exosome-carried microRNAs. Currently, several experimental systems are commercially available that simplify the identification, isolation, and characterization of Tregs using fluorescent-conjugated antibodies for CD4, CD25, FOXP3, CD127, cytotoxic T-lymphocyte associated molecule-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR), CD39, and CD45RA [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Originally termed suppressor T cells, the recognition of regulatory T cells as a cellular mechanism for immune tolerance resulted from experiments performed in the 1960s and 1970s by Gerson and Kondo, which described the induction of suppressor T cells capable of downregulation of antigen-specific T cell responses [<xref ref-type="bibr" rid="CR8">8</xref>]. Due to the lack of known molecular markers, research on suppressor T cells ceased. However, in 1995, Sagakuchi et al<italic>.</italic> identified CD25 as a surface phenotypic marker for suppressive CD4 cells in mice [<xref ref-type="bibr" rid="CR9">9</xref>]. Since then, suppressive T cells have been called regulatory T cells (Tregs). Since the first characterization of Tregs in 1995 [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>], one of the major milestones in Tregs studies was the identification of FOXP3. FOXP3 is a member of the forkhead/winged-helix family of transcription factors, which acts as a &#x0201c;master regulator&#x0201d; (for multiple pathways) for the development and suppressive function of Tregs [<xref ref-type="bibr" rid="CR11">11</xref>-<xref ref-type="bibr" rid="CR13">13</xref>]. The significance of FOXP3 gene was identified by its mutations that cause fatal autoimmune diseases in early life, which is now termed immunodysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome in mice and humans. Since the discovery of the FOXP3 gene, its role and modification have been one of the potential topics in translational medicine field due to the essential function of FOXP3 in maintaining immune tolerance and homeostasis. Similar to T-bet (a T-box gene encoded transcription factor) [<xref ref-type="bibr" rid="CR14">14</xref>], GATA3 (a trans-acting T cell-specific transcription factor) [<xref ref-type="bibr" rid="CR15">15</xref>], and ROR&#x003b3;t (a RAR-related nuclear orphan receptor family member) [<xref ref-type="bibr" rid="CR16">16</xref>] identified as the subset-specific transcription factors for the terminal differentiation of type 1 CD4 T helper cells (Th1), Th2, and Th17, respectively, identification of FOXP3 as a Treg-specific transcription factor was a logic approach for the establishment of Tregs as a terminally differentiated and lineage committed subset of CD4 T cells.</p><p>Due to its significant roles in controlling inflammation, innate and adaptive immune responses, and immune tolerance, many unsolved questions remain to be the focus of investigations [<xref ref-type="bibr" rid="CR17">17</xref>], such as 1) whether Tregs have to be generated in the central lymphoid organ like thymus or Tregs can be &#x0201c;converted&#x0201d; from non-Tregs in peripheral tissues [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>]. Recently, a special population of Tregs was found in injured muscle, which is distinct from other Treg population and potentiates muscle repair. This report not only revealed a new function of Tregs in modulating tissue repair but also proposed a new pathway for Treg generation [<xref ref-type="bibr" rid="CR20">20</xref>]; 2) whether there are tissue-resident Tregs, in other words, whether tissue physiological environment modulates Tregs&#x02019; genotypes and phenotypes; 3) how do Tregs maintain their own homeostasis. In 2008, we analyzed more than 90 factors involved in regulating homeostasis of Tregs, suggesting that the repertoires of Tregs are undergoing constant adjustment [<xref ref-type="bibr" rid="CR21">21</xref>]and finally three mechanistic issues were addressed; 4) whether Tregs have functional receptors to sense pathogen-associated molecular patterns (PAMPs) or danger signal-associated molecular patterns (DAMPs) and participate in inflammation [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>]; 5) whether Tregs are a non-changeable lineage committed subset or have differentiation plasticity; and 6) whether epigenetic mechanisms [<xref ref-type="bibr" rid="CR19">19</xref>] regulate Tregs&#x02019; response to changes in physiological tissue environments and pathological conditions such as inflammation. Of note, Treg homeostatic changes have been reported in various diseases [<xref ref-type="bibr" rid="CR24">24</xref>-<xref ref-type="bibr" rid="CR66">66</xref>] as shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, in which the PMIDs of the papers/reviews are listed. Based on the significant progresses, we have proposed for the first time a novel concept that &#x0201c;physiological Tregs&#x0201d; have been modulated into &#x0201c;pathological Tregs&#x0201d; in various pathological environments. As shown in our novel working model in Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, both physiological and pathological Tregs may undergo changes in differentiation/subset plasticity, homeostasis (survival/death), and proliferation dynamics via molecular mechanisms including pathogen (danger)-associated molecular pattern (PAMPs/DAMPs) receptor signaling, epigenetic mechanisms, microRNAs, and other noncoding RNAs. The issue of how pathological conditions re-shape the subsets of physiological Tregs remains to be poorly addressed. Pathological Tregs can have four different functional status including a) functional suppressors, b) weakened suppressors, c) tumor-enhanced suppressors, and d) malignant Tregs. Improvement of our understanding on these important issues would eventually lead to the future development of Tregs-based novel therapeutics for treating acute and chronic inflammatory diseases, allergy, allogeneic transplantation-related immunity, sepsis, autoimmune diseases, and cancers. For more historical details on the research progress of Tregs, one may refer to others&#x02019; excellent reviews as well as ours [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Treg homeostatic changes have been found in various diseases</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Pathological conditions</bold>
</th><th>
<bold>Major phenotypes</bold>
</th><th>
<bold>PMIDs</bold>
</th><th>
<bold>Reference #</bold>
</th></tr></thead><tbody><tr valign="top"><td>Atherosclerosis coronary disease (CAD)</td><td>Tregs in chronic stable angina patients &#x02192;</td><td>20539016</td><td>[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td/><td>Tregs in patients with ST-elevation acute myocardial infarction &#x02191;</td><td/><td/></tr><tr valign="top"><td/><td>Tregs in patients with non-ST-elevation acute coronary syndrome patients &#x02193;</td><td/><td/></tr><tr valign="top"><td/><td>Ratio of CD4<sup>+</sup>CD2S<sup>+</sup>Foxp3<sup>+</sup>/CD4<sup>+</sup> T cells in patients with acute coronary syndrome &#x02193;</td><td>18294918</td><td>[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD2S<sup>+</sup>Foxp3<sup>+</sup> Tregs in patients with unstable CAD &#x02193;</td><td>17512253</td><td>[<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr valign="top"><td>End stage kidney disease</td><td rowspan="2">Tregs sensitivity to Fas-mediated apoptosis</td><td rowspan="2">20429423</td><td rowspan="2">[<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr valign="top"><td>Type II diabetes</td></tr><tr valign="top"><td/><td>Ratio of CD4<sup>+</sup>CD2S<sup>high</sup> Treg/Th17 &#x02193;</td><td>21964948</td><td>[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr valign="top"><td/><td>Ratio of CD4<sup>+</sup>CD2S<sup>high</sup> Treg/Th1 &#x02193;</td><td>21169542</td><td>[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr valign="top"><td/><td>Peripheral induced CD4<sup>+</sup>Foxp3<sup>+</sup>Helios<sup>&#x02212;</sup> Tregs &#x02193;</td><td/><td/></tr><tr valign="top"><td/><td>Bcl-2/Bax ratio in CD4<sup>+</sup>CD2S<sup>high</sup> Tregs &#x02193;</td><td/><td/></tr><tr valign="top"><td>Obesity-linked insulin resistance</td><td>Natural Tregs&#x02193;</td><td>21911743</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr valign="top"><td/><td>Adaptive Tregs in visceral adipose tissue &#x02191;</td><td/><td/></tr><tr valign="top"><td>Obesity</td><td>Circulating C04<sup>+</sup>CD25&#x000f7;CD127-Foxp3<sup>+</sup> Tregs &#x02193; and inversely correlated with body weight</td><td>23592653</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr valign="top"><td/><td>Visceral adipose Tregs &#x02193;</td><td>21298111</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr valign="top"><td>Allergy</td><td>Individuals may develop allergy (Th2 predominant) or recovery (Tr1 predominant) depending on the balance between allergen-specific Th2 and Tr1</td><td>15173208, 14987885</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr valign="top"><td/><td/><td>12704370</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD25<sup>+</sup> Tregs inhibit TH1 and TH2, cytokine production in atopic patients</td><td/><td/></tr><tr valign="top"><td>SLE (lupus)</td><td>CD4<sup>+</sup>CD2S<sup>+</sup>, CD4<sup>+</sup>CD69<sup>+</sup> and CD4<sup>+</sup>CD2S<sup>high</sup> Tregs &#x02193;</td><td>14599852</td><td>[<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr valign="top"><td/><td>The frequency &#x02192;, and function of CD4<sup>+</sup>CD25<sup>+</sup> cells &#x02193;, CD4<sup>+</sup>Foxp3<sup>+</sup> &#x02192;</td><td>16890406</td><td>[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr valign="top"><td/><td>The ratio and number of CD4<sup>+</sup>CD25<sup>high</sup>Foxp3<sup>+</sup> nTregs &#x02193;</td><td>17670847</td><td>[<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr valign="top"><td/><td>The ratio of CD4<sup>+</sup>IL-1G&#x000f7; iTregs, but the number &#x02192;</td><td/><td/></tr><tr valign="top"><td>Rheumatoid arthritis</td><td>CD4<sup>+</sup>CD2s<sup>bright</sup> Tregs cell in joint fluid &#x02191;</td><td>15807863,</td><td>[<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD2s<sup>bright</sup> Tregs cell in peripheral blood &#x02193;</td><td>15225369, 16571607</td><td>[<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr><tr valign="top"><td/><td>Function of CD4<sup>+</sup>CD25<sup>+</sup>Tregs &#x02193;</td><td>15280421</td><td>[<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr valign="top"><td>Severe juvenile idiopathic arthritis</td><td>CD4<sup>+</sup>CD25<sup>bright</sup> &#x02193;</td><td>15128835</td><td>[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr valign="top"><td>Sepsis</td><td>Ratio of circulating CD4.CD25&#x000f7;CD45RO<sup>+</sup>CD69<sup>&#x02212;</sup> Tregs/CD4<sup>+</sup>CD25&#x02014; Teffectorst &#x02191;</td><td>12847405, 15640650</td><td>[<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr valign="top"><td/><td/><td>18946659</td><td>[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr valign="top"><td/><td>Increased CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>&#x02212;</sup>Foxp3<sup>+</sup> Tregs contribute to lymphocyte anergy Percentage of CD4<sup>+</sup>CD25<sup>+</sup> Treg &#x02191;</td><td>15640650</td><td>[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr valign="top"><td/><td>Resistance of Treg to apoptosis processes</td><td>11292647, 15817707</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr valign="top"><td>Injury</td><td>CD4<sup>+</sup>CD25<sup>+</sup> Treg function &#x02191; after burn injury</td><td>16365414</td><td>[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr valign="top"><td/><td>CD3<sup>+</sup>CD4<sup>+</sup>CD2S<sup>high</sup>CDl27<sup>low</sup>Foxp3<sup>+</sup> &#x02191; in patients with acute lung injury</td><td>19770521</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr valign="top"><td>Graft rejection</td><td>The frequencies and proportion of CD4<sup>+</sup>CD2S<sup>+</sup>Foxp3<sup>+</sup> Tregs &#x02192; in allograft acceptors and rejecters, but the Foxp3 expression levels in Tregs in acceptor patients are 50% higher than rejecter patients</td><td>19109145</td><td>[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr valign="top"><td/><td>Cotransfer of purified CD4<sup>+</sup>CD2S<sup>+</sup> Tregs along with the CD4<sup>+</sup>CD25<sup>&#x02212;</sup> T cells significantly delay graft versus host disease</td><td>11390438</td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr valign="top"><td/><td>Inducible Tregs prolong allograft survival without newly formed innate Tregs entering the periphery</td><td>14707064</td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr valign="top"><td/><td>TCR<sup>+</sup>CD4<sup>&#x02212;</sup>CD8<sup>&#x02212;</sup> Tregs mediate acceptance of skin allografts by inducing the deletion of alloreactive CD8<sup>+</sup> T cells</td><td>10888927</td><td>[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr valign="top"><td/><td>FoxP3<sup>+</sup> Treg/CD3<sup>+</sup> T cell ratio positively correlated with graft function at 2 years after transplantation</td><td>18495961</td><td>[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr valign="top"><td>Cancer</td><td>CD4<sup>+</sup>CD25<sup>high</sup> Tregs &#x02191; in circulating and tumor infiltrating lymphocytes (TILs) in patients with epithelial malignancies, inhibiting the proliferation of conventional T cells and IFN-y production</td><td>11466340</td><td>[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD25<sup>high</sup> Tregs with positive lL.10/TGF-p/CTLA-4 &#x02191; in peripheral blood, lymph nodes and tumor tissue in patients with pancreatic and breast cancer</td><td>12193750</td><td>[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr valign="top"><td/><td>IL-lO-producing CD4<sup>+</sup>CD2S<sup>high</sup> Tregs &#x02191; in PB, TILs, draining LNs, and ascites fluid in gastro-esophageal cancers, which were strongly associated to disease stage</td><td>14555512, 15734494, 16328385, 12942579</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>-<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs &#x02191; in PB, malignant ascites, tumoral tissue, and draining INs in patients with ovarian cancer patients</td><td>15322536</td><td>[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr valign="top"><td/><td>Circulating CD4<sup>+</sup>CD25<sup>high</sup> Tregs &#x02191; in chronic lymphocytic leukemia (CLI), B cell-derived non-Hodgkin lymphomas (B-NHL5)</td><td>15914560, 16403912, 17047079</td><td>[<xref ref-type="bibr" rid="CR62">62</xref>-<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr valign="top"><td/><td>CD4<sup>+</sup>CD25<sup>high</sup>CD45<sup>&#x02212;</sup>RA<sup>&#x02212;</sup>CD69<sup>&#x02212;</sup>CD45RO<sup>+</sup>CD9S<sup>+</sup> Tregs &#x02191; in acute myeloid leukemia and present higher apoptosis and proliferation</td><td>16313258</td><td>[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr></tbody></table><table-wrap-foot><p>&#x02191;: significant increase, &#x02193;: significant decrease, &#x02192;: no change.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>Our novel working model has been proposed: &#x0201c;Pathological conditions re-shape physiological Tregs into pathological Tregs&#x0201d;.</p></caption><graphic xlink:href="41038_2015_1_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec2"><title>Review</title><sec id="Sec3"><title>tTregs, pTregs, iTregs, and iTreg35</title><p>FOXP3<sup>+</sup>CD28<sup>+</sup>Granzyme B<sup>+</sup>TGF&#x003b2;-insensitive naturally occurring thymus-generated Tregs (tTregs or nTregs) [<xref ref-type="bibr" rid="CR67">67</xref>] are characterized by the expression of CD4, and transcriptional factor FOXP3 and high expression of CD25 [<xref ref-type="bibr" rid="CR68">68</xref>]. Initially identified for their co-expression of CD4 and CD25 cell surface markers, in subsequent reports tTregs have been recognized by other surface markers such as CD103, CD62L, lymphocyte activation gene 3 protein (LAG 3), C-C chemokine receptor type 5 (CCR5), neurophilin-1 [<xref ref-type="bibr" rid="CR69">69</xref>-<xref ref-type="bibr" rid="CR71">71</xref>], the activation antigens glucocorticoid-induced tumor necrosis factor receptor (TNFR) family related gene (GITR), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (also known as CD152), as well as the lack of certain cell surface markers such as CD127 (the &#x003b1; chain of the IL-7 receptor) [<xref ref-type="bibr" rid="CR72">72</xref>].Of note, Helios, a member of Ikaros transcription factor family is proposed to be a marker of tTregs [<xref ref-type="bibr" rid="CR73">73</xref>], which can be used to distinguish tTregs from iTregs [<xref ref-type="bibr" rid="CR67">67</xref>]. Fully matured FOXP3<sup>+</sup> tTregs exit the thymus and migrate to the secondary lymphoid organs where they suppress the proliferation of tissue-specific autoimmune T cells, restrain their differentiation into type 1 T helper cells (Th1), Th2, and Th17 lineages <italic>in vivo</italic> [<xref ref-type="bibr" rid="CR74">74</xref>], and inhibit polyclonal T cell activation and T-effector cell trafficking [<xref ref-type="bibr" rid="CR67">67</xref>]. They recognize specific self-antigens and prevent autoimmunity by the inhibition of pathogenic lymphocytes. In addition to adaptive immune cells such as T cells and B cells, tTregs also inhibit the function of innate immune cells including antigen-presenting cells such as macrophages and dendritic cells (DCs) by modulating expression of MARCHI and CD83 on macrophages and DCs [<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR74">74</xref>].</p><p>So far, the modes of how do tTregs suppress effector cells have been identified: inhibition of cytokine production, prevention of cytotoxic T cells proliferation, and inactivation of antigen-presenting cell function. In addition, Tregs contribute to effector T cells apoptosis via three mechanisms including Fas-FasL-mediated killing, suppressive cytokine-induced impairment [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref>], and microRNA transmitted in exosomes [<xref ref-type="bibr" rid="CR77">77</xref>]. As we reviewed [<xref ref-type="bibr" rid="CR18">18</xref>], the role of tTregs in suppressing chronic inflammation has been clearly demonstrated in experimental atherosclerosis model in 2006 by Ait-Oufellaet et al., which showed an increase in atherosclerotic lesion size and vulnerability in proatherogenic apolipoprotein E deficient (ApoE&#x02212;/&#x02212;) mice after peripheral Tregs were depleted [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR78">78</xref>].</p><p>FOXP3<sup>+</sup>CTLA4<sup>+</sup>IL-10<sup>+</sup>TGF&#x003b2;-sensitive adaptive, inducible, or peripheral Tregs (iTregs/aTregs/pTregs) [<xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR80">80</xref>] are induced by T cell antigen receptor (TCR) ligation (antigen-specific Tregs) [<xref ref-type="bibr" rid="CR67">67</xref>] and TGF&#x003b2; stimulation in periphery from CD4<sup>+</sup>CD25<sup>&#x02212;</sup> T cell precursors [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR79">79</xref>], which acquire the upregulation of CD25 (interleukin-2 receptor &#x003b1; chain (IL-2R&#x003b1;)). Inducible Tregs are developed from na&#x000ef;ve CD4 T cells in the lymphoid tissues in response to specific antigens in the presence of cytokines such as transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1), interleukin-10 (IL-10), and IL-4, while in the absence of pro-inflammatory cytokines such as interferon-&#x003b3; (IFN-&#x003b3;), IL-1, IL-6, and IL-12. This antigen presentation in the absence of danger signals is referred as tolerogenic, which is essential for the suppression of undesired immune reactivity against non-harmful materials such as airborne particles, commensal bacteria, and foods. In addition, iTregs depend on IL-2 for development and survival as previously reported [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR81">81</xref>-<xref ref-type="bibr" rid="CR83">83</xref>], which also explains why iTregs highly express CD25 and probably other IL-2 receptor components. Furthermore, iTregs may be able to redirect macrophage differentiation toward an anti-inflammatory cytokine-producing type 2 macrophage phenotype (M2) rather than pro-inflammatory type 1 macrophages (M1 phenotype) [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Different subsets of iTregs have been reported including T regulatory cell type 1 (Tr1) and T helper cell type 3 (Th3) [<xref ref-type="bibr" rid="CR84">84</xref>]. Tr1 cells are CD25<sup>&#x02212;</sup>FOXP3<sup>&#x02212;</sup>CD49b<sup>+</sup>LAG-3<sup>+</sup>T cells characterized by the secretion of large amounts of IL-10, some IL-5 and IFN-&#x003b3; with or without TGF-&#x003b2;, IL-2, or IL-4 [<xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref>]. Tr1 cells control the activation of na&#x000ef;ve and memory T cells <italic>in vivo</italic> and <italic>in vitro</italic> and also suppress the Th1 and Th2 immune responses to pathogens, tumors, and alloantigen-expressed transplanted tissues [<xref ref-type="bibr" rid="CR87">87</xref>]. The capacity of DCs to induce T cell proliferation is strongly reduced by the supernatant of activated Tr1 [<xref ref-type="bibr" rid="CR88">88</xref>], suggesting that Tr1 suppression is mediated by secreted cytokines. Th3 cells have been shown to produce high amounts of TGF-&#x003b2; when induced by oral tolerance in mucosal tissue in an antigen-specific manner [<xref ref-type="bibr" rid="CR74">74</xref>]. In addition, CD4<sup>+</sup>LAP<sup>+</sup> (latency-associated peptide) Tregs have been identified recently as the third iTregs subtype whose suppression is mediated by TGF-&#x003b2; in immune diseases including experimental autoimmune encephalitis (EAE), type I diabetes mellitus (T1DM), systemic lupus erythematosus (SLE), collagen-induced arthritis, type II diabetes, and atherosclerosis in mice [<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR89">89</xref>].</p><p>Most recently, a new suppressive cytokine IL-35 [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref>] has defined a new IL-35-producing iTregs subset, iTreg35 [<xref ref-type="bibr" rid="CR75">75</xref>], and a subset of IL-35-producing B regulatory cells (Breg) [<xref ref-type="bibr" rid="CR90">90</xref>,<xref ref-type="bibr" rid="CR91">91</xref>]. These induced cell subsets are probably responsive to acute and chronic inflammation stimuli since we previously reported that IL-35 is a new category of suppressive cytokine termed responsive cytokine in contrast to the house-keeping suppressive cytokine TGF-&#x003b2; [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec4"><title>Tissue-resident Tregs</title><p>Similar or parallel to the classification of tTregs, pTregs, iTregs, and iTreg35, it has been proposed that Tregs can also be classified into three new subsets, central Tregs, effector Tregs, and tissue-resident Tregs [<xref ref-type="bibr" rid="CR17">17</xref>]. Of note, every new classification of cell subsets reflects the improvement of our understanding on the features of the cells. Central Tregs, also termed as resting Tregs or na&#x000ef;ve Tregs, make up the majority of Tregs in the circulation and secondary lymphoid organs. Central Tregs have a phenotype of CD62L<sup>high</sup>CCR7<sup>+</sup> (C-C chemokine receptor type 7) or CD45RA<sup>high</sup>CD25<sup>low</sup>. Effector (memory) Tregs constitute a minor fraction of Tregs in the circulation and secondary lymphoid organs, which have a phenotype of CD62L<sup>low</sup>CCR7<sup>low</sup>CD44<sup>high</sup>KLRG1<sup>+</sup> (killer cell lectin-like receptor subfamily G member1-positive) CD103<sup>+</sup> or CD45RA<sup>low</sup>CD25<sup>high</sup>. Tissue-resident Tregs specify those Tregs that have a long-term residence in non-lymphoid tissues. So far, four types of tissue-resident Tregs have been identified: 1) skin/lung Tregs are specified by two transcription factors FOXP3 and T-bet. The trafficking of skin/lung Tregs are controlled by CXCR3 (receptor for the C-X-C chemokine CXCL9, CXCL10, and CXCL11) and CCR4 (chemokine (C-C motif) receptor 4). The homeostatic mediators for skin/lung Tregs include CD40L, IFN-&#x00264;, IL-27, and IL-7; 2) gut Tregs are specified by two transcription factors, FOXP3 and Signal transducer and activator of transcription 3 (STAT3). The trafficking of gut Tregs are controlled by CCR6. The homeostatic mediators for gut Tregs include short-chain fatty acid (SCFA), IL-10, IL-6, and IL-1; 3) germinal center Tregs are specified by two transcription factors, FOXP3 and BCL-6. The trafficking of germinal center Tregs are controlled by CXCR5. The homeostatic mediators for germinal center Tregs are still unknown; and 4) adipose tissue Tregs [<xref ref-type="bibr" rid="CR92">92</xref>] are specified by two transcription factors, FOXP3 and peroxisome proliferator-activated receptor gamma (PPAR&#x00264;). The chemokine receptors for trafficking of adipose tissue Tregs are unknown. The homeostatic mediators for adipose tissue Tregs include lipids and long-chain fatty acid (LCFA) [<xref ref-type="bibr" rid="CR17">17</xref>]. In the near future, we will see more characterizations of tissue-resident Tregs. Identification of tissue-resident Tregs suggests that Tregs express additional transcription factors, chemokine receptors, and receptors for homeostatic mediators in order to respond to the signals of tissue physiological environments.</p></sec><sec id="Sec5"><title>Highly dynamic and apoptotic populations of Tregs</title><p>Our previous reports showed that CD25<sup>+/high</sup> Tregs are a cell population that are &#x0201c;hungry&#x0201d; for IL-2 for survival and undergo apoptosis easily by upregulating pro-apoptotic protein Bax [<xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR93">93</xref>] and downregulating anti-apoptotic cytosolic protein translationally controlled tumor protein (TCTP) [<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR94">94</xref>]. Postulating from our updated understanding on CD25<sup>low</sup> central Tregs and CD25<sup>high</sup> effector Tregs, our results suggest that CD25<sup>low</sup> central Tregs are less likely to undergo acute coronary syndrome- [<xref ref-type="bibr" rid="CR95">95</xref>], end stage renal disease- [<xref ref-type="bibr" rid="CR27">27</xref>], and chronic inflammation/infection-related [<xref ref-type="bibr" rid="CR17">17</xref>], IL-2 decrease-triggered Treg apoptosis [<xref ref-type="bibr" rid="CR96">96</xref>-<xref ref-type="bibr" rid="CR98">98</xref>] than CD25<sup>high</sup> effector Tregs. Based on our results and others&#x02019; reports, we proposed that the Tregs apoptotic pathways are novel therapeutic targets for the future development of novel therapy in treating inflammation, autoimmune disease, transplantation-related diseases, allergy, and cancers [<xref ref-type="bibr" rid="CR21">21</xref>]. Our findings were confirmed by recent excellent reports on high rates of Tregs apoptosis. These reports show that Treg-specific transcription factor FOXP3 is a pro-apoptotic protein [<xref ref-type="bibr" rid="CR99">99</xref>]; and that mitochondrial anti-apoptosis-regulatory pathway protein Mcl-1 is critical for Tregs survival and niche-filling capacity [<xref ref-type="bibr" rid="CR100">100</xref>]. However, future work is still needed to determine the apoptotic rates for each subset of Tregs.</p><p>High apoptotic rates of Tregs raises the question of how these Tregs maintain their population sizes. Using a special technique to follow up the Thy-1 expressing recent thymic cell emigrants (RTE), investigators found that approximately 30% of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> Tregs express the markers associated with RTE. Following thymectomy, the numbers of cells expressing these markers fell by 80% within 30 days. In addition, although only ~5% of CD4 single-positive thymocytes express FOXP3 within 24 h after intrathymic injection of fluorescence dye fluorescein isothiocyanate (FITC), more than 30% of the labeled CD4<sup>+</sup>RTE are FOXP3<sup>+</sup>, suggesting that some RTE may acquire FOXP3 expression in the periphery. Thus, some RTE may acquire FOXP3 rapidly after emigration from thymus. Tregs are dividing rapidly with apparent half-lives of ~18 days and ~7 days for the CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> and CD4<sup>+</sup>CD25<sup>&#x02212;</sup>FOXP3<sup>+</sup> subsets, respectively. The apparent slower turnover of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> cells is a result of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> to CD4<sup>+</sup>CD25<sup>&#x02212;</sup>FOXP3<sup>+</sup> conversion, with no loss of regulatory function. Therefore, the data suggested that Tregs in adults are relatively short-lived and Tregs numbers are maintained by rapid cell division and continuous replenishment from the thymus [<xref ref-type="bibr" rid="CR101">101</xref>].</p></sec><sec id="Sec6"><title>Pathogen-associated molecular pattern receptors on Tregs</title><p>After a long time of extensive research, it has been widely accepted that the host innate immune system is equipped with a set of receptors to recognize PAMPs derived from viruses, bacteria, other invasive microorganisms and environmental stimuli or metabolite-related DAMPs [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>]. So far, four types of receptors for PAMPs and DAMPs have been identified; Toll-like receptors (TLRs, 13 members), nucleotide-binding oligomerization domain (NOD) leucine-rich-repeat containing receptors (NLRs, 18 members), C-type lectin receptors (5 members), and retinoic acid-inducible gene I protein (RIG-I) helicase receptors (2 members) [<xref ref-type="bibr" rid="CR102">102</xref>]. An important question remains whether Tregs are equipped with these sets of receptors for PAMPs and DAMPs. It was reported that stimulation of human Tregs with a mixture of TLR2 ligands Pam2CSK4, Pam3CSK4, and FSL-1 can result in a reversal of suppression on anti-CD3/anti-CD28 stimulated responder T cells. However, the gastric mucosa of the infected TLR2 knock-out mice showed a lower mRNA expression of FOXP3, IL-10, and IL-17A, but a higher expression of IFN-&#x003b3; compared to the gastric mRNA expression in infected wild-type mice [<xref ref-type="bibr" rid="CR103">103</xref>]. In addition, TLR5 and TLR8 also modulate the suppressive activity of naturally occurring CD4<sup>+</sup>CD25<sup>high</sup> Tregs. The suppressive capacity of Tregs is counter-regulated by TLR ligands indirectly via antigen-presenting cells (APCs) or responder T cells or directly [<xref ref-type="bibr" rid="CR104">104</xref>]. Similarly, TLR4 stimulation of T effector cells and Tregs co-culture leads to a more pronounced T effector cell activation [<xref ref-type="bibr" rid="CR105">105</xref>]. TLR ligand lipopolysaccharide (LPS) stimulation of TLR4 on Tregs, similar to T cell antigen receptor ligation, can enhance Tregs suppression on neutrophils [<xref ref-type="bibr" rid="CR106">106</xref>]. It is obvious that this field is still in the early stage. Further studies are needed to determine the roles of the receptors for PAMPs and DAMPs in regulating Tregs homeostasis and suppressive function.</p></sec><sec id="Sec7"><title>Tregs plasticity and FOXP3 expression regulated by other transcription factors</title><p>Current understandings suggest that na&#x000ef;ve CD4 T helper cells can differentiate/polarize into at least six different terminally differentiated/lineage-committed subsets. 1) Na&#x000ef;ve CD4 T helper cells can differentiate into type 1 T helper cell subset (Th1) with the expression of Th1-specific transcription factor T-bet in the presence of IL-12 and IFN-&#x003b3;. 2) Na&#x000ef;ve CD4 T cells can differentiate into Th2 subset with the expression of Th2-specific transcription factor GATA3 in the presence of IL-4. 3) Na&#x000ef;ve CD4 T cells can differentiate into Th17 subset with the expression of Th17-specific transcription factor ROR&#x003b3;t in the presence of IL-6 and TGF-&#x003b2;. 4) Na&#x000ef;ve CD4 T cells can differentiate into iTregs subset with the expression of Treg-specific transcription factor FOXP3 in the presence of TGF-&#x003b2;, retinoic acid, and IL-2. 5) Na&#x000ef;ve CD4 T cells can also differentiate into follicular T helper cells (Tfh) subset in the presence of IL-21. Na&#x000ef;ve CD4<sup>+</sup> T cells and Th2 can differentiate into Th9 cells in the presence of TGF-&#x003b2; [<xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR108">108</xref>].</p><p>Among all these CD4 subsets, Th1 and Th2 are relatively stable, but iTregs and Th17 cells can readily switch to other T helper subsets under certain cytokine stimulations. In the presence of B cells and CD40-CD40L interaction, iTregs can switch to follicular T helper (Tfh) cells mediated by transcription factor B-cell lymphoma/leukemia 6 (BCL-6) [<xref ref-type="bibr" rid="CR109">109</xref>]. In addition, iTregs can also switch to IL-17-producing cells (Th17) mediated by transcription factor STAT3 [<xref ref-type="bibr" rid="CR109">109</xref>] after stimulation with IL-6 and IL-21. Moreover, iTregs can also convert to Th2 cells mediated by transcription factor Irf4 [<xref ref-type="bibr" rid="CR109">109</xref>]. Furthermore, iTregs can switch to Th1 cells mediated by T-bet [<xref ref-type="bibr" rid="CR109">109</xref>]. Finally, Th17 can convert into IFN-&#x003b3;-producing Th1 cells or IL-4-producing Th2 cells when stimulated by IL-12 or IL-4, respectively. Th2 cells convert to IL-9-producing cells in response to TGF-&#x003b2; stimulation [<xref ref-type="bibr" rid="CR108">108</xref>]. This conversion of terminally differentiated lineage committed subset to other terminally differentiated lineage committed subsets is termed &#x0201c;plasticity&#x0201d;. Several factors participate in the regulation of T cell conversion including extrinsic and intrinsic ones. The extrinsic factors include accessory immune cells, innate receptors for PAMPs and DAMPs, cytokine microenvironment including the cytokines in polarizing other T helper subsets, cytokine receptor regulation, nutrient availability, and metabolic pathways including long-chain fatty acids and short-chain fatty acids for adipose tissue Tregs. The intrinsic factors are cell cycle and phenotype stability, microRNA mediated control of T cell phenotype, transcription factor dosing and dominance, and epigenetic modifications [<xref ref-type="bibr" rid="CR109">109</xref>].</p><p>In fact, numerous transcription factors have been identified in reshaping Tregs development, function, and homeostasis. These include the first group of transcription factors functional in regulating FOXP3 expression and the second group of transcription factors in forming a complex with FOXP3. Some of the factors are overlapped in these two groups. The first group includes nuclear factor of activated T cells (NFAT), c-Rel (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)), activator protein 1 (AP-1), Nr4a (a subfamily of the orphan nuclear receptors), and signal transducer and activator of transcription 5 (STAT5), and FOXP3. In addition to the regulation of FOXP3 gene expression, recent reports indicate that FOXP3 itself is able to form complexes with a number of co-factors to execute cooperative effects during their interaction [<xref ref-type="bibr" rid="CR110">110</xref>]. The second group of FOXP3 co-factors is composed of as many as 11 sequence specific transcription factors including NFATc2, runt-related transcription factor 1 (RUNX1; also known as acute myeloid leukemia 1 protein (AML1) or core-binding factor subunit alpha-2 (CBFA2)), B-cell lymphoma/leukemia 11B (BCL11b), Foxp1, Foxp4, GATA-3, STAT3, Ikaros (Ikzf1; a lymphoid transcription factor LyF-1), Aiolos (Ikzf3; the Ikaros, Aiolos and Helios are three family members of the hematopoietic specific transcription factors involved in the regulation of lymphocyte development), Ets (E26 transformation-specific family of transcription factors), and Cnot3 (CCR4-NOT transcription complex, subunit 3). The majority of FOXP3 binding sites within the genome lack an identifiable forkhead-binding motif in Tregs, which suggests that a large number of FOXP3 co-factors facilitate the binding of FOXP3 to a given site [<xref ref-type="bibr" rid="CR111">111</xref>-<xref ref-type="bibr" rid="CR113">113</xref>]. Since some of these transcription factors, if not all, are also inflammation-regulatory transcription factors [<xref ref-type="bibr" rid="CR114">114</xref>], it suggests that the inflammation and pathological conditions can regulate the plasticity of Tregs and other T cells. In support of this argument, the expression of Treg-specific transcription factor FOXP3 requires demethylation of FOXP3 promoter [<xref ref-type="bibr" rid="CR115">115</xref>] whereas proatherogenic stimuli like oxidized low-density lipoprotein (oxLDL) induces increased methylation of FOXP3 promoter and decreased FOXP3 expression [<xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec8"><title>Epigenetic regulation and microRNA regulation of Tregs</title><p>Under inflammatory stimulations, the suppressive function of Tregs is decreased and TGF-&#x003b2;-induced Tregs development is attenuated by an epigenetic manner [<xref ref-type="bibr" rid="CR117">117</xref>]. It suggests that epigenetic regulation of Tregs function, development, and homeostasis is patho-physiologically relevant. In correlation with this finding, Tregs suppression is also reported to be attenuated in autoimmune type 1 diabetes, in which epigenetics is one of the pathological mechanisms involved [<xref ref-type="bibr" rid="CR118">118</xref>]. What is epigenetics? Epigenetics refers to heritable changes that occur in gene expression without modification in the DNA sequence of the genome. These epigenetics mechanisms, which briefly include DNA methylation/demethylation, histones modifications, and micro-RNAs (miRNAs) are the principal mechanisms involved in regulating chromosomal organization, chromosomal remodeling and then gene expression via different dynamic levels. More specifically, it has been demonstrated that epigenetics mechanisms play a critical role in regulating FOXP3 expression and lead to further regulations in Tregs functions and homeostasis [<xref ref-type="bibr" rid="CR119">119</xref>-<xref ref-type="bibr" rid="CR121">121</xref>]. Emerging epigenetics therapies are providing new therapeutic agents for the control of various diseases [<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR81">81</xref>-<xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR122">122</xref>].</p><p>The term epigenetics was first introduced by Conrad Waddington in 1942 [<xref ref-type="bibr" rid="CR123">123</xref>]. Epigenetics [<xref ref-type="bibr" rid="CR123">123</xref>] integrates organism genotypes by the influence and response of environmental stimuli on their phenotype, which can take place in chromosomal DNA or in the proteins linked with the chromosomal DNA such as histones. In recent years, many epigenetic proteins have been investigated in laboratories and in clinic, while inhibitor development for modification enzymes is the frontier for drug discovery. So far, epigenetic modifications have been grouped into four main categories: DNA methylation, histone modification including histone methylation/demethylation, histone acetylation/deacetylation, histone phosphorylation, histone SUMOylation [<xref ref-type="bibr" rid="CR124">124</xref>], small and long noncoding RNAs, as well as chromatin remodeling [<xref ref-type="bibr" rid="CR124">124</xref>,<xref ref-type="bibr" rid="CR125">125</xref>].</p><p>Noncoding RNAs (ncRNAs) are a type of functional RNA molecule, which are not translated into proteins. More functional groups of ncRNAs have been categorized by the following: four short noncoding RNAs (17&#x02013;31 base pairs (bp)) (microRNAs (miRNAs), Piwi-interacting RNAs (piRNAs), small interfering RNAs (siRNAs), and transcription initiation RNAs), mid-size noncoding RNAs (&#x0003c;200 bp) (small nucleolar RNAs, promoter-associated small RNAs (PASRs), TSS-associated RNAs (TSSa-RNAs), and promoter upstream transcripts (PROMPTs)), long noncoding RNAs (lncRNAs, &#x0003e;200 bp), and its subgroups such as long intergenic noncoding RNAs (lincRNAs), enhancer RNAs (eRNAs), transcribed ultraconserved regions (T-UCRs) and other lncRNAs [<xref ref-type="bibr" rid="CR126">126</xref>]. It has been widely shown that ncRNAs not only regulate gene expression at the transcriptional and post-transcriptional levels but also play a role in the control of epigenetic pathways [<xref ref-type="bibr" rid="CR127">127</xref>]. Of note, we recently published a comprehensive review on epigenetics enzymes as new therapeutic targets for Treg-based therapy, which one may refer to for the details [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec></sec><sec id="Sec9"><title>Conclusions</title><p>The roles of Tregs in inhibiting inflammation, autoimmune diseases, allergy, transplantation, and modulating anti-cancer immune responses have been well established. Due to extensive studies, several new concepts and principles regarding Tregs in physiological and pathological status have emerged, which are concisely discussed in this brief review. Continuation in improving our understanding on the molecular mechanisms underlying Tregs development, homeostasis, and functions will eventually lead to the future development of novel Tregs-based therapeutics to treat inflammation, chronic cardiovascular diseases, allergy, allogeneic transplantation-related immune responses, sepsis, autoimmune diseases, and cancers.</p></sec></body><back><fn-group><fn><p>William Y Yang and Ying Shao contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>WY and YS carried out the primary literature search and drafted the manuscript. JL and JM provided material input, and helped revising the manuscript. HW and XFY conceived the study, provided field expertise, and finalized the manuscript. All authors read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>WY is a Research Assistant. YS, MS, is an Assistant Scientist. JL, MD, is a Postdoc Fellow. JM, PHD, is a Postdoc Fellow. HW, MD, PhD, EMBA, FAHA, is a Professor. XFY, MD, PhD, EMBA, FAHA, is a Professor.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work is partially supported by NIH grants to Drs. XF. Yang and H. Wang.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Setoguchi</surname><given-names>R</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name></person-group><article-title>Naturally arising Foxp3-expressing CD25&#x02009;+&#x02009;CD4+ regulatory T cells in self-tolerance and autoimmune disease</article-title><source>Curr Top Microbiol Immunol</source><year>2006</year><volume>305</volume><fpage>51</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">16724800</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Vascular inflammation and atherogenesis are activated via receptors for pamps and suppressed by regulatory t cells</article-title><source>Drug Discov Today Ther Strat</source><year>2008</year><volume>5</volume><issue>2</issue><fpage>125</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ddstr.2008.11.003</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askenasy</surname><given-names>N</given-names></name></person-group><article-title>Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity</article-title><source>Autoimmun Rev</source><year>2013</year><volume>12</volume><issue>10</issue><fpage>972</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2013.04.005</pub-id><pub-id pub-id-type="pmid">23684702</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Mai</surname><given-names>J</given-names></name><name><surname>Virtue</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Sha</surname><given-names>X</given-names></name><etal/></person-group><article-title>IL-35 is a novel responsive anti-inflammatory cytokine&#x02013;a new system of categorizing anti-inflammatory cytokines</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>3</issue><fpage>e33628</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0033628</pub-id><pub-id pub-id-type="pmid">22438968</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignali</surname><given-names>DA</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>IL-12 family cytokines: immunological playmakers</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><issue>8</issue><fpage>722</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ni.2366</pub-id><pub-id pub-id-type="pmid">22814351</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name><name><surname>Guy</surname><given-names>CS</given-names></name><name><surname>Vignali</surname><given-names>KM</given-names></name><name><surname>Chaturvedi</surname><given-names>V</given-names></name><name><surname>Fairweather</surname><given-names>D</given-names></name><etal/></person-group><article-title>The composition and signaling of the IL-35 receptor are unconventional</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><issue>3</issue><fpage>290</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ni.2227</pub-id><pub-id pub-id-type="pmid">22306691</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonetta</surname><given-names>F</given-names></name><name><surname>Chiali</surname><given-names>A</given-names></name><name><surname>Cordier</surname><given-names>C</given-names></name><name><surname>Urrutia</surname><given-names>A</given-names></name><name><surname>Girault</surname><given-names>I</given-names></name><name><surname>Bloquet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Increased CD127 expression on activated FOXP3&#x02009;+&#x02009;CD4+ regulatory T cells</article-title><source>Eur J Immunol</source><year>2010</year><volume>40</volume><issue>9</issue><fpage>2528</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/eji.201040531</pub-id><pub-id pub-id-type="pmid">20690182</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershon</surname><given-names>RK</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name></person-group><article-title>Cell interactions in the induction of tolerance: the role of thymic lymphocytes</article-title><source>Immunology</source><year>1970</year><volume>18</volume><issue>5</issue><fpage>723</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">4911896</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>N</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name></person-group><article-title>Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><issue>3</issue><fpage>1151</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">7636184</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Naturally arising Foxp3-expressing CD25&#x02009;+&#x02009;CD4+ regulatory T cells in immunological tolerance to self and non-self</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><issue>4</issue><fpage>345</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/ni1178</pub-id><pub-id pub-id-type="pmid">15785760</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoh</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>FOXP3: genetic and epigenetic implications for autoimmunity</article-title><source>J Autoimmun</source><year>2013</year><volume>41</volume><fpage>72</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2012.12.004</pub-id><pub-id pub-id-type="pmid">23313429</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>van der Touw</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><issue>1</issue><fpage>259</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.182.1.259</pub-id><pub-id pub-id-type="pmid">19109157</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The FOX transcription factors regulate vascular pathology, diabetes and Tregs</article-title><source>Front Biosci (Schol Ed)</source><year>2009</year><volume>1</volume><fpage>420</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2741/s35</pub-id><pub-id pub-id-type="pmid">19482711</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarevic</surname><given-names>V</given-names></name><name><surname>Glimcher</surname><given-names>LH</given-names></name><name><surname>Lord</surname><given-names>GM</given-names></name></person-group><article-title>T-bet: a bridge between innate and adaptive immunity</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><issue>11</issue><fpage>777</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/nri3536</pub-id><pub-id pub-id-type="pmid">24113868</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanhere</surname><given-names>A</given-names></name><name><surname>Hertweck</surname><given-names>A</given-names></name><name><surname>Bhatia</surname><given-names>U</given-names></name><name><surname>Gokmen</surname><given-names>MR</given-names></name><name><surname>Perucha</surname><given-names>E</given-names></name><name><surname>Jackson</surname><given-names>I</given-names></name><etal/></person-group><article-title>T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements</article-title><source>Nat Commun</source><year>2012</year><volume>3</volume><fpage>1268</fpage><pub-id pub-id-type="doi">10.1038/ncomms2260</pub-id><pub-id pub-id-type="pmid">23232398</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name></person-group><article-title>Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity</article-title><source>Front Biosci (Landmark Ed)</source><year>2010</year><volume>15</volume><fpage>986</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.2741/3657</pub-id><pub-id pub-id-type="pmid">20515737</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liston</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>DH</given-names></name></person-group><article-title>Homeostatic control of regulatory T cell diversity</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>154</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nri3605</pub-id><pub-id pub-id-type="pmid">24481337</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastrana</surname><given-names>JL</given-names></name><name><surname>Sha</surname><given-names>X</given-names></name><name><surname>Virtue</surname><given-names>A</given-names></name><name><surname>Mai</surname><given-names>J</given-names></name><name><surname>Cueto</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Regulatory T cells and atherosclerosis</article-title><source>J Clin Exp Cardiol</source><year>2012</year><volume>2012</volume><issue>Suppl 12</issue><fpage>2</fpage></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Pastrana JL, Shao Y, Chernaya V, Wang H, Yang XF. Epigenetic enzymes are the therapeutic targets for CD4CD25Foxp3 regulatory T cells. Transl Res. 2014. Epub 2014/09/07.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burzyn</surname><given-names>D</given-names></name><name><surname>Kuswanto</surname><given-names>W</given-names></name><name><surname>Kolodin</surname><given-names>D</given-names></name><name><surname>Shadrach</surname><given-names>JL</given-names></name><name><surname>Cerletti</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A special population of regulatory T cells potentiates muscle repair</article-title><source>Cell</source><year>2013</year><volume>155</volume><issue>6</issue><fpage>1282</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.054</pub-id><pub-id pub-id-type="pmid">24315098</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XF</given-names></name></person-group><article-title>Factors regulating apoptosis and homeostasis of CD4&#x02009;+&#x02009;CD25highFOXP3+ regulatory T cells are new therapeutic targets</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>1472</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.2741/2775</pub-id><pub-id pub-id-type="pmid">17981643</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Mai</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>NC</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inflammasomes are differentially expressed in cardiovascular and other tissues</article-title><source>Int J Immunopathol Pharmacol</source><year>2009</year><volume>22</volume><issue>2</issue><fpage>311</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19505385</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Pastrana</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Mallilankaraman</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Inflammasomes: sensors of metabolic stresses for vascular inflammation</article-title><source>Front Biosci</source><year>2013</year><volume>18</volume><fpage>638</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.2741/4127</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammirati</surname><given-names>E</given-names></name><name><surname>Cianflone</surname><given-names>D</given-names></name><name><surname>Banfi</surname><given-names>M</given-names></name><name><surname>Vecchio</surname><given-names>V</given-names></name><name><surname>Palini</surname><given-names>A</given-names></name><name><surname>De Metrio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Circulating CD4&#x02009;+&#x02009;CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2010</year><volume>30</volume><issue>9</issue><fpage>1832</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.110.206813</pub-id><pub-id pub-id-type="pmid">20539016</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>YJ</given-names></name><name><surname>Fu</surname><given-names>QQ</given-names></name><name><surname>Xie</surname><given-names>JJ</given-names></name><name><surname>Tang</surname><given-names>TT</given-names></name><etal/></person-group><article-title>The Th17/Treg imbalance in patients with acute coronary syndrome</article-title><source>Clin Immunol</source><year>2008</year><volume>127</volume><issue>1</issue><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2008.01.009</pub-id><pub-id pub-id-type="pmid">18294918</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SF</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Bu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>The opposite-direction modulation of CD4&#x02009;+&#x02009;CD25+ Tregs and T helper 1 cells in acute coronary syndromes</article-title><source>Clin Immunol</source><year>2007</year><volume>124</volume><issue>1</issue><fpage>90</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2007.03.546</pub-id><pub-id pub-id-type="pmid">17512253</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>FOXP3+ regulatory T-cells in chronic kidney disease: molecular pathways and clinical implications</article-title><source>Adv Exp Med Biol</source><year>2009</year><volume>665</volume><fpage>163</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-1599-3_12</pub-id><pub-id pub-id-type="pmid">20429423</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><etal/></person-group><article-title>The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications</article-title><source>J Mol Med (Berl)</source><year>2012</year><volume>90</volume><issue>2</issue><fpage>175</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00109-011-0816-5</pub-id><pub-id pub-id-type="pmid">21964948</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagannathan-Bogdan</surname><given-names>M</given-names></name><name><surname>McDonnell</surname><given-names>ME</given-names></name><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Rehman</surname><given-names>Q</given-names></name><name><surname>Hasturk</surname><given-names>H</given-names></name><name><surname>Apovian</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><issue>2</issue><fpage>1162</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002615</pub-id><pub-id pub-id-type="pmid">21169542</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eller</surname><given-names>K</given-names></name><name><surname>Kirsch</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>AM</given-names></name><name><surname>Sopper</surname><given-names>S</given-names></name><name><surname>Tagwerker</surname><given-names>A</given-names></name><name><surname>Stanzl</surname><given-names>U</given-names></name><etal/></person-group><article-title>Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><issue>11</issue><fpage>2954</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.2337/db11-0358</pub-id><pub-id pub-id-type="pmid">21911743</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Wagner NM, Brandhorst G, Czepluch F, Lankeit M, Eberle C, Herzberg S, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring, Md. 2013;21(3):461-8. Epub 2013/04/18.</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deiuliis</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>Z</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Needleman</surname><given-names>B</given-names></name><name><surname>Mikami</surname><given-names>D</given-names></name><name><surname>Narula</surname><given-names>V</given-names></name><etal/></person-group><article-title>Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>e16376</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0016376</pub-id><pub-id pub-id-type="pmid">21298111</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Verhagen</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Karamloo</surname><given-names>F</given-names></name><name><surname>Karagiannidis</surname><given-names>C</given-names></name><name><surname>Crameri</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><issue>11</issue><fpage>1567</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1084/jem.20032058</pub-id><pub-id pub-id-type="pmid">15173208</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>XD</given-names></name><name><surname>Pridgeon</surname><given-names>C</given-names></name><name><surname>Dallman</surname><given-names>M</given-names></name><name><surname>Arbery</surname><given-names>J</given-names></name><etal/></person-group><article-title>Relation of CD4&#x02009;+&#x02009;CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9409</issue><fpage>608</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15592-X</pub-id><pub-id pub-id-type="pmid">14987885</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellinghausen</surname><given-names>I</given-names></name><name><surname>Klostermann</surname><given-names>B</given-names></name><name><surname>Knop</surname><given-names>J</given-names></name><name><surname>Saloga</surname><given-names>J</given-names></name></person-group><article-title>Human CD4&#x02009;+&#x02009;CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><issue>4</issue><fpage>862</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1067/mai.2003.1412</pub-id><pub-id pub-id-type="pmid">12704370</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crispin</surname><given-names>JC</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Alcocer-Varela</surname><given-names>J</given-names></name></person-group><article-title>Quantification of regulatory T cells in patients with systemic lupus erythematosus</article-title><source>J Autoimmun</source><year>2003</year><volume>21</volume><issue>3</issue><fpage>273</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0896-8411(03)00121-5</pub-id><pub-id pub-id-type="pmid">14599852</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado-Sanchez</surname><given-names>B</given-names></name><name><surname>Hernandez-Castro</surname><given-names>B</given-names></name><name><surname>Portales-Perez</surname><given-names>D</given-names></name><name><surname>Baranda</surname><given-names>L</given-names></name><name><surname>Layseca-Espinosa</surname><given-names>E</given-names></name><name><surname>Abud-Mendoza</surname><given-names>C</given-names></name><etal/></person-group><article-title>Regulatory T cells in patients with systemic lupus erythematosus</article-title><source>J Autoimmun</source><year>2006</year><volume>27</volume><issue>2</issue><fpage>110</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2006.06.005</pub-id><pub-id pub-id-type="pmid">16890406</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barath</surname><given-names>S</given-names></name><name><surname>Aleksza</surname><given-names>M</given-names></name><name><surname>Tarr</surname><given-names>T</given-names></name><name><surname>Sipka</surname><given-names>S</given-names></name><name><surname>Szegedi</surname><given-names>G</given-names></name><name><surname>Kiss</surname><given-names>E</given-names></name></person-group><article-title>Measurement of natural (CD4&#x02009;+&#x02009;CD25high) and inducible (CD4&#x02009;+&#x02009;IL-10+) regulatory T cells in patients with systemic lupus erythematosus</article-title><source>Lupus</source><year>2007</year><volume>16</volume><issue>7</issue><fpage>489</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1177/0961203307080226</pub-id><pub-id pub-id-type="pmid">17670847</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottonen</surname><given-names>M</given-names></name><name><surname>Heikkinen</surname><given-names>J</given-names></name><name><surname>Mustonen</surname><given-names>L</given-names></name><name><surname>Isomaki</surname><given-names>P</given-names></name><name><surname>Luukkainen</surname><given-names>R</given-names></name><name><surname>Lassila</surname><given-names>O</given-names></name></person-group><article-title>CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>140</volume><issue>2</issue><fpage>360</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02754.x</pub-id><pub-id pub-id-type="pmid">15807863</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>van Vollenhoven</surname><given-names>R</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Trollmo</surname><given-names>C</given-names></name><name><surname>Malmstrom</surname><given-names>V</given-names></name></person-group><article-title>CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease</article-title><source>Arthritis Res Ther</source><year>2004</year><volume>6</volume><issue>4</issue><fpage>R335</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1186/ar1192</pub-id><pub-id pub-id-type="pmid">15225369</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>CA</given-names></name><name><surname>Brown</surname><given-names>AK</given-names></name><name><surname>Bejarano</surname><given-names>V</given-names></name><name><surname>Douglas</surname><given-names>SH</given-names></name><name><surname>Burgoyne</surname><given-names>CH</given-names></name><name><surname>Greenstein</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Early rheumatoid arthritis is associated with a deficit in the CD4&#x02009;+&#x02009;CD25high regulatory T cell population in peripheral blood</article-title><source>Rheumatology (Oxford)</source><year>2006</year><volume>45</volume><issue>10</issue><fpage>1210</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kel089</pub-id><pub-id pub-id-type="pmid">16571607</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenstein</surname><given-names>MR</given-names></name><name><surname>Evans</surname><given-names>JG</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Warnes</surname><given-names>G</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy</article-title><source>J Exp Med</source><year>2004</year><volume>200</volume><issue>3</issue><fpage>277</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1084/jem.20040165</pub-id><pub-id pub-id-type="pmid">15280421</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Kleer</surname><given-names>IM</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Varsani</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD4&#x02009;+&#x02009;CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><issue>10</issue><fpage>6435</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.10.6435</pub-id><pub-id pub-id-type="pmid">15128835</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monneret</surname><given-names>G</given-names></name><name><surname>Debard</surname><given-names>AL</given-names></name><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Bohe</surname><given-names>J</given-names></name><name><surname>Hequet</surname><given-names>O</given-names></name><name><surname>Bienvenu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Marked elevation of human circulating CD4&#x02009;+&#x02009;CD25+ regulatory T cells in sepsis-induced immunoparalysis</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>7</issue><fpage>2068</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000069345.78884.0F</pub-id><pub-id pub-id-type="pmid">12847405</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Pachot</surname><given-names>A</given-names></name><name><surname>Debard</surname><given-names>AL</given-names></name><name><surname>Bohe</surname><given-names>J</given-names></name><name><surname>Bienvenu</surname><given-names>J</given-names></name><name><surname>Lepape</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased percentage of CD4&#x02009;+&#x02009;CD25+ regulatory T cells during septic shock is due to the decrease of CD4&#x02009;+&#x02009;CD25- lymphocytes</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><issue>11</issue><fpage>2329</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000145999.42971.4B</pub-id><pub-id pub-id-type="pmid">15640650</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Chung</surname><given-names>CS</given-names></name><name><surname>Kherouf</surname><given-names>H</given-names></name><name><surname>Geeraert</surname><given-names>A</given-names></name><name><surname>Malcus</surname><given-names>C</given-names></name><name><surname>Poitevin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><issue>4</issue><fpage>678</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1337-8</pub-id><pub-id pub-id-type="pmid">18946659</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberholzer</surname><given-names>C</given-names></name><name><surname>Oberholzer</surname><given-names>A</given-names></name><name><surname>Clare-Salzler</surname><given-names>M</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name></person-group><article-title>Apoptosis in sepsis: a new target for therapeutic exploration</article-title><source>Faseb J</source><year>2001</year><volume>15</volume><issue>6</issue><fpage>879</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1096/fj.00-058rev</pub-id><pub-id pub-id-type="pmid">11292647</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesche</surname><given-names>DE</given-names></name><name><surname>Lomas-Neira</surname><given-names>JL</given-names></name><name><surname>Perl</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>CS</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name></person-group><article-title>Leukocyte apoptosis and its significance in sepsis and shock</article-title><source>J Leukoc Biol</source><year>2005</year><volume>78</volume><issue>2</issue><fpage>325</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1189/jlb.0105017</pub-id><pub-id pub-id-type="pmid">15817707</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni Choileain</surname><given-names>N</given-names></name><name><surname>MacConmara</surname><given-names>M</given-names></name><name><surname>Zang</surname><given-names>Y</given-names></name><name><surname>Murphy</surname><given-names>TJ</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name></person-group><article-title>Enhanced regulatory T cell activity is an element of the host response to injury</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><issue>1</issue><fpage>225</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.1.225</pub-id><pub-id pub-id-type="pmid">16365414</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Alessio</surname><given-names>FR</given-names></name><name><surname>Tsushima</surname><given-names>K</given-names></name><name><surname>Aggarwal</surname><given-names>NR</given-names></name><name><surname>West</surname><given-names>EE</given-names></name><name><surname>Willett</surname><given-names>MH</given-names></name><name><surname>Britos</surname><given-names>MF</given-names></name><etal/></person-group><article-title>CD4&#x02009;+&#x02009;CD25&#x02009;+&#x02009;Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>10</issue><fpage>2898</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1172/JCI36498</pub-id><pub-id pub-id-type="pmid">19770521</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>SK</given-names></name><name><surname>Saban</surname><given-names>DR</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Dana</surname><given-names>R</given-names></name></person-group><article-title>Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><issue>1</issue><fpage>148</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.182.1.148</pub-id><pub-id pub-id-type="pmid">19109145</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PA</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name></person-group><article-title>CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><issue>11</issue><fpage>1311</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1084/jem.193.11.1311</pub-id><pub-id pub-id-type="pmid">11390438</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>M</given-names></name><name><surname>Kingsley</surname><given-names>CI</given-names></name><name><surname>Bushell</surname><given-names>AR</given-names></name><name><surname>Sawitzki</surname><given-names>BS</given-names></name><name><surname>Wood</surname><given-names>KJ</given-names></name></person-group><article-title>Alloantigen-induced CD25&#x02009;+&#x02009;CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><issue>2</issue><fpage>923</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.2.923</pub-id><pub-id pub-id-type="pmid">14707064</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZX</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Young</surname><given-names>KJ</given-names></name><name><surname>DuTemple</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><issue>7</issue><fpage>782</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/77513</pub-id><pub-id pub-id-type="pmid">10888927</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestard</surname><given-names>O</given-names></name><name><surname>Cruzado</surname><given-names>JM</given-names></name><name><surname>Rama</surname><given-names>I</given-names></name><name><surname>Torras</surname><given-names>J</given-names></name><name><surname>Goma</surname><given-names>M</given-names></name><name><surname>Seron</surname><given-names>D</given-names></name><etal/></person-group><article-title>Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><issue>10</issue><fpage>2020</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007111174</pub-id><pub-id pub-id-type="pmid">18495961</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>CD4&#x02009;+&#x02009;CD25high regulatory cells in human peripheral blood</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><issue>3</issue><fpage>1245</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.3.1245</pub-id><pub-id pub-id-type="pmid">11466340</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liyanage</surname><given-names>UK</given-names></name><name><surname>Moore</surname><given-names>TT</given-names></name><name><surname>Joo</surname><given-names>HG</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Herrmann</surname><given-names>V</given-names></name><name><surname>Doherty</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><issue>5</issue><fpage>2756</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.5.2756</pub-id><pub-id pub-id-type="pmid">12193750</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>F</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Kawaida</surname><given-names>H</given-names></name><name><surname>Sugai</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name></person-group><article-title>Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><issue>12</issue><fpage>4404</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14555512</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaida</surname><given-names>H</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Sugai</surname><given-names>H</given-names></name><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Miyagawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Distribution of CD4&#x02009;+&#x02009;CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer</article-title><source>J Surg Res</source><year>2005</year><volume>124</volume><issue>1</issue><fpage>151</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2004.10.004</pub-id><pub-id pub-id-type="pmid">15734494</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Kawaida</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Sugai</surname><given-names>H</given-names></name><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Miyagawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers</article-title><source>Cancer Immunol Immunother</source><year>2006</year><volume>55</volume><issue>9</issue><fpage>1064</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0092-8</pub-id><pub-id pub-id-type="pmid">16328385</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasada</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Takabayashi</surname><given-names>A</given-names></name></person-group><article-title>CD4&#x02009;+&#x02009;CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression</article-title><source>Cancer</source><year>2003</year><volume>98</volume><issue>5</issue><fpage>1089</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/cncr.11618</pub-id><pub-id pub-id-type="pmid">12942579</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><etal/></person-group><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>9</issue><fpage>942</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nm1093</pub-id><pub-id pub-id-type="pmid">15322536</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Darabi</surname><given-names>K</given-names></name><name><surname>Popov</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Endl</surname><given-names>E</given-names></name><etal/></person-group><article-title>Reduced frequencies and suppressive function of CD4&#x02009;+&#x02009;CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine</article-title><source>Blood</source><year>2005</year><volume>106</volume><issue>6</issue><fpage>2018</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-02-0642</pub-id><pub-id pub-id-type="pmid">15914560</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZZ</given-names></name><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Stenson</surname><given-names>MJ</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Ansell</surname><given-names>SM</given-names></name></person-group><article-title>Intratumoral CD4&#x02009;+&#x02009;CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma</article-title><source>Blood</source><year>2006</year><volume>107</volume><issue>9</issue><fpage>3639</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-08-3376</pub-id><pub-id pub-id-type="pmid">16403912</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZZ</given-names></name><name><surname>Novak</surname><given-names>AJ</given-names></name><name><surname>Ziesmer</surname><given-names>SC</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Ansell</surname><given-names>SM</given-names></name></person-group><article-title>Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>20</issue><fpage>10145</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1822</pub-id><pub-id pub-id-type="pmid">17047079</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients</article-title><source>Eur J Haematol</source><year>2005</year><volume>75</volume><issue>6</issue><fpage>468</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2005.00537.x</pub-id><pub-id pub-id-type="pmid">16313258</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Thornton</surname><given-names>AM</given-names></name></person-group><article-title>tTregs, pTregs, and iTregs: similarities and differences</article-title><source>Immunol Rev</source><year>2014</year><volume>259</volume><issue>1</issue><fpage>88</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/imr.12160</pub-id><pub-id pub-id-type="pmid">24712461</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>GL</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name></person-group><article-title>Foxp3+ regulatory T cells: selfishness under scrutiny</article-title><source>Immunity</source><year>2007</year><volume>27</volume><issue>3</issue><fpage>417</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.08.008</pub-id><pub-id pub-id-type="pmid">17892850</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tordjman</surname><given-names>R</given-names></name><name><surname>Lepelletier</surname><given-names>Y</given-names></name><name><surname>Lemarchandel</surname><given-names>V</given-names></name><name><surname>Cambot</surname><given-names>M</given-names></name><name><surname>Gaulard</surname><given-names>P</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><etal/></person-group><article-title>A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><issue>5</issue><fpage>477</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11953749</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Davini</surname><given-names>D</given-names></name><name><surname>Gardner</surname><given-names>JM</given-names></name><name><surname>Martinez-Llordella</surname><given-names>M</given-names></name><name><surname>Bailey-Bucktrout</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo</article-title><source>J Exp Med</source><year>2012</year><volume>209</volume><issue>10</issue><fpage>1713</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1084/jem.20120822</pub-id><pub-id pub-id-type="pmid">22966003</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>JM</given-names></name><name><surname>Bilate</surname><given-names>AM</given-names></name><name><surname>Gobert</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>de Lafaille MA</surname><given-names>C</given-names></name><name><surname>Parkhurst</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells</article-title><source>J Exp Med</source><year>2012</year><volume>209</volume><issue>10</issue><fpage>1723</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1084/jem.20120914</pub-id><pub-id pub-id-type="pmid">22966001</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses</article-title><source>Annu Rev Immunol</source><year>2004</year><volume>22</volume><fpage>531</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141122</pub-id><pub-id pub-id-type="pmid">15032588</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>AM</given-names></name><name><surname>Korty</surname><given-names>PE</given-names></name><name><surname>Tran</surname><given-names>DQ</given-names></name><name><surname>Wohlfert</surname><given-names>EA</given-names></name><name><surname>Murray</surname><given-names>PE</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><issue>7</issue><fpage>3433</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0904028</pub-id><pub-id pub-id-type="pmid">20181882</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Sasaki N, Yamashita T, Takeda M, Hirata K. Regulatory T cells in atherogenesis. Journal of atherosclerosis and thrombosis. 2012;19(6):503-15. Epub 2012/04/14.</mixed-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Chaturvedi</surname><given-names>V</given-names></name><name><surname>Henderson</surname><given-names>AL</given-names></name><name><surname>Giacomin</surname><given-names>PR</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Bankoti</surname><given-names>J</given-names></name><etal/></person-group><article-title>IL-35-mediated induction of a potent regulatory T cell population</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><issue>12</issue><fpage>1093</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/ni.1952</pub-id><pub-id pub-id-type="pmid">20953201</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Kuo</surname><given-names>TT</given-names></name><name><surname>Boyd</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Vignali</surname><given-names>KM</given-names></name><etal/></person-group><article-title>The inhibitory cytokine IL-35 contributes to regulatory T-cell function</article-title><source>Nature</source><year>2007</year><volume>450</volume><issue>7169</issue><fpage>566</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature06306</pub-id><pub-id pub-id-type="pmid">18033300</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okoye</surname><given-names>IS</given-names></name><name><surname>Coomes</surname><given-names>SM</given-names></name><name><surname>Pelly</surname><given-names>VS</given-names></name><name><surname>Czieso</surname><given-names>S</given-names></name><name><surname>Papayannopoulos</surname><given-names>V</given-names></name><name><surname>Tolmachova</surname><given-names>T</given-names></name><etal/></person-group><article-title>MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells</article-title><source>Immunity</source><year>2014</year><volume>41</volume><issue>1</issue><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.05.019</pub-id><pub-id pub-id-type="pmid">25035954</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Salomon</surname><given-names>BL</given-names></name><name><surname>Potteaux</surname><given-names>S</given-names></name><name><surname>Robertson</surname><given-names>AK</given-names></name><name><surname>Gourdy</surname><given-names>P</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><etal/></person-group><article-title>Natural regulatory T cells control the development of atherosclerosis in mice</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><issue>2</issue><fpage>178</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nm1343</pub-id><pub-id pub-id-type="pmid">16462800</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lafaille MA</surname><given-names>C</given-names></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name></person-group><article-title>Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?</article-title><source>Immunity</source><year>2009</year><volume>30</volume><issue>5</issue><fpage>626</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.002</pub-id><pub-id pub-id-type="pmid">19464985</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Hibino</surname><given-names>S</given-names></name><name><surname>Someya</surname><given-names>K</given-names></name><name><surname>Yoshmura</surname><given-names>A</given-names></name></person-group><article-title>Regulation of regulatory T cells: epigenetics and plasticity</article-title><source>Adv Immunol</source><year>2014</year><volume>124</volume><fpage>249</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-800147-9.00008-X</pub-id><pub-id pub-id-type="pmid">25175778</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cowan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Higher expression of Bax in regulatory T cells increases vascular inflammation</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>7143</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.2741/3217</pub-id><pub-id pub-id-type="pmid">18508723</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Expression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammation</article-title><source>Atherosclerosis</source><year>2009</year><volume>203</volume><issue>2</issue><fpage>401</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.07.041</pub-id><pub-id pub-id-type="pmid">18789801</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Thornton</surname><given-names>AM</given-names></name><etal/></person-group><article-title>CD25high T cells with a prolonged survival inhibit development of diabetes</article-title><source>Int J Immunopathol Pharmacol</source><year>2008</year><volume>21</volume><issue>4</issue><fpage>767</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19144262</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonuleit</surname><given-names>H</given-names></name><name><surname>Schmitt</surname><given-names>E</given-names></name></person-group><article-title>The regulatory T cell family: distinct subsets and their interrelations</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><issue>12</issue><fpage>6323</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.12.6323</pub-id><pub-id pub-id-type="pmid">14662827</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hippen</surname><given-names>KL</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name></person-group><article-title>Clinical perspectives for regulatory T cells in transplantation tolerance</article-title><source>Semin Immunol</source><year>2011</year><volume>23</volume><issue>6</issue><fpage>462</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2011.07.008</pub-id><pub-id pub-id-type="pmid">21820917</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagliani</surname><given-names>N</given-names></name><name><surname>Magnani</surname><given-names>CF</given-names></name><name><surname>Huber</surname><given-names>S</given-names></name><name><surname>Gianolini</surname><given-names>ME</given-names></name><name><surname>Pala</surname><given-names>M</given-names></name><name><surname>Licona-Limon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><issue>6</issue><fpage>739</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/nm.3179</pub-id><pub-id pub-id-type="pmid">23624599</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groux</surname><given-names>H</given-names></name></person-group><article-title>Type 1 T-regulatory cells: their role in the control of immune responses</article-title><source>Transplantation</source><year>2003</year><volume>75</volume><issue>9 Suppl</issue><fpage>8S</fpage><lpage>12S</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000067944.90241.BD</pub-id><pub-id pub-id-type="pmid">12819483</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roncarolo</surname><given-names>MG</given-names></name><name><surname>Levings</surname><given-names>MK</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name></person-group><article-title>Differentiation of T regulatory cells by immature dendritic cells</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><issue>2</issue><fpage>F5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1084/jem.193.2.F5</pub-id><pub-id pub-id-type="pmid">11208869</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name></person-group><article-title>The autocrine regulatory effect of vasoactive intestinal peptide on the growth of human pancreatic carcinoma cells</article-title><source>Chin Med Sci J</source><year>1994</year><volume>9</volume><issue>4</issue><fpage>215</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7718859</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>RX</given-names></name><name><surname>Yu</surname><given-names>CR</given-names></name><name><surname>Dambuza</surname><given-names>IM</given-names></name><name><surname>Mahdi</surname><given-names>RM</given-names></name><name><surname>Dolinska</surname><given-names>MB</given-names></name><name><surname>Sergeev</surname><given-names>YV</given-names></name><etal/></person-group><article-title>Interleukin-35 induces regulatory B cells that suppress autoimmune disease</article-title><source>Nat Med</source><year>2014</year><volume>20</volume><issue>6</issue><fpage>633</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nm.3554</pub-id><pub-id pub-id-type="pmid">24743305</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Roch</surname><given-names>T</given-names></name><name><surname>Lampropoulou</surname><given-names>V</given-names></name><name><surname>O'Connor</surname><given-names>RA</given-names></name><name><surname>Stervbo</surname><given-names>U</given-names></name><name><surname>Hilgenberg</surname><given-names>E</given-names></name><etal/></person-group><article-title>IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases</article-title><source>Nature</source><year>2014</year><volume>507</volume><issue>7492</issue><fpage>366</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature12979</pub-id><pub-id pub-id-type="pmid">24572363</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><article-title>Immunological goings-on in visceral adipose tissue</article-title><source>Cell Metab</source><year>2013</year><volume>17</volume><issue>6</issue><fpage>851</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.05.008</pub-id><pub-id pub-id-type="pmid">23747244</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Weber</surname><given-names>GF</given-names></name><name><surname>Cantor</surname><given-names>H</given-names></name></person-group><article-title>A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells</article-title><source>Immunity</source><year>1997</year><volume>7</volume><issue>5</issue><fpage>629</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80384-2</pub-id><pub-id pub-id-type="pmid">9390687</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><etal/></person-group><article-title>An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>30</issue><fpage>4778</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208666</pub-id><pub-id pub-id-type="pmid">15870695</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>A</given-names></name><name><surname>Luboshits</surname><given-names>G</given-names></name><name><surname>Planer</surname><given-names>D</given-names></name><name><surname>Keren</surname><given-names>G</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>21</issue><fpage>2530</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehl222</pub-id><pub-id pub-id-type="pmid">16954132</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malek</surname><given-names>TR</given-names></name><name><surname>Bayer</surname><given-names>AL</given-names></name></person-group><article-title>Tolerance, not immunity, crucially depends on IL-2</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><issue>9</issue><fpage>665</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nri1435</pub-id><pub-id pub-id-type="pmid">15343366</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>T</given-names></name><name><surname>Hucko</surname><given-names>T</given-names></name><name><surname>Schneemann</surname><given-names>C</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Menrad</surname><given-names>A</given-names></name><name><surname>Willuda</surname><given-names>J</given-names></name><etal/></person-group><article-title>Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells</article-title><source>Atherosclerosis</source><year>2012</year><volume>220</volume><issue>2</issue><fpage>329</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.09.050</pub-id><pub-id pub-id-type="pmid">22062588</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koreth</surname><given-names>J</given-names></name><name><surname>Matsuoka</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>McDonough</surname><given-names>SM</given-names></name><name><surname>Bindra</surname><given-names>B</given-names></name><name><surname>Alyea</surname><given-names>EP</given-names><suffix>3rd</suffix></name><etal/></person-group><article-title>Interleukin-2 and regulatory T cells in graft-versus-host disease</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>22</issue><fpage>2055</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1108188</pub-id><pub-id pub-id-type="pmid">22129252</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>X</given-names></name><name><surname>Erman</surname><given-names>B</given-names></name><name><surname>Alag</surname><given-names>A</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals</article-title><source>Immunity</source><year>2013</year><volume>38</volume><issue>6</issue><fpage>1116</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.022</pub-id><pub-id pub-id-type="pmid">23746651</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>W</given-names></name><name><surname>Cauwe</surname><given-names>B</given-names></name><name><surname>Policheni</surname><given-names>A</given-names></name><name><surname>Schlenner</surname><given-names>SM</given-names></name><name><surname>Franckaert</surname><given-names>D</given-names></name><name><surname>Berges</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3(+) regulatory T cells</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><issue>9</issue><fpage>959</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/ni.2649</pub-id><pub-id pub-id-type="pmid">23852275</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabarrack</surname><given-names>NH</given-names></name><name><surname>Turner</surname><given-names>NL</given-names></name><name><surname>Mayrhofer</surname><given-names>G</given-names></name></person-group><article-title>Recent thymic origin, differentiation, and turnover of regulatory T cells</article-title><source>J Leukoc Biol</source><year>2008</year><volume>84</volume><issue>5</issue><fpage>1287</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1189/jlb.0308201</pub-id><pub-id pub-id-type="pmid">18682578</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>van der Meer</surname><given-names>JW</given-names></name></person-group><article-title>Immunodeficiency and genetic defects of pattern-recognition receptors</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>1</issue><fpage>60</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1001976</pub-id><pub-id pub-id-type="pmid">21208109</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>El-Zataari</surname><given-names>M</given-names></name><name><surname>Owyang</surname><given-names>SY</given-names></name><name><surname>Eaton</surname><given-names>KA</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>9</issue><fpage>e74595</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0074595</pub-id><pub-id pub-id-type="pmid">24058595</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberg</surname><given-names>HH</given-names></name><name><surname>Juricke</surname><given-names>M</given-names></name><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>Wesch</surname><given-names>D</given-names></name></person-group><article-title>Regulation of T cell activation by TLR ligands</article-title><source>Eur J Cell Biol</source><year>2011</year><volume>90</volume><issue>6-7</issue><fpage>582</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.ejcb.2010.11.012</pub-id><pub-id pub-id-type="pmid">21292344</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordiglieri</surname><given-names>C</given-names></name><name><surname>Marolda</surname><given-names>R</given-names></name><name><surname>Franzi</surname><given-names>S</given-names></name><name><surname>Cappelletti</surname><given-names>C</given-names></name><name><surname>Giardina</surname><given-names>C</given-names></name><name><surname>Motta</surname><given-names>T</given-names></name><etal/></person-group><article-title>Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity</article-title><source>J Autoimmun</source><year>2014</year><volume>52</volume><fpage>74</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2013.12.013</pub-id><pub-id pub-id-type="pmid">24397961</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewkowicz</surname><given-names>P</given-names></name><name><surname>Lewkowicz</surname><given-names>N</given-names></name><name><surname>Sasiak</surname><given-names>A</given-names></name><name><surname>Tchorzewski</surname><given-names>H</given-names></name></person-group><article-title>Lipopolysaccharide-activated CD4&#x02009;+&#x02009;CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><issue>10</issue><fpage>7155</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.10.7155</pub-id><pub-id pub-id-type="pmid">17082633</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luckheeram</surname><given-names>RV</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Verma</surname><given-names>AD</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name></person-group><article-title>CD4(+)T cells: differentiation and functions</article-title><source>Clin Dev Immunol</source><year>2012</year><volume>2012</volume><fpage>925135</fpage><pub-id pub-id-type="doi">10.1155/2012/925135</pub-id><pub-id pub-id-type="pmid">22474485</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Chong</surname><given-names>MM</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><article-title>Plasticity of CD4+ T cell lineage differentiation</article-title><source>Immunity</source><year>2009</year><volume>30</volume><issue>5</issue><fpage>646</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.001</pub-id><pub-id pub-id-type="pmid">19464987</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coomes</surname><given-names>SM</given-names></name><name><surname>Pelly</surname><given-names>VS</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name></person-group><article-title>Plasticity within the alphabeta(+)CD4(+) T-cell lineage: when, how and what for?</article-title><source>Open Biol</source><year>2013</year><volume>3</volume><issue>1</issue><fpage>120157</fpage><pub-id pub-id-type="doi">10.1098/rsob.120157</pub-id><pub-id pub-id-type="pmid">23345540</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudra</surname><given-names>D</given-names></name><name><surname>deRoos</surname><given-names>P</given-names></name><name><surname>Chaudhry</surname><given-names>A</given-names></name><name><surname>Niec</surname><given-names>RE</given-names></name><name><surname>Arvey</surname><given-names>A</given-names></name><name><surname>Samstein</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Transcription factor Foxp3 and its protein partners form a complex regulatory network</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>1010</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ni.2402</pub-id><pub-id pub-id-type="pmid">22922362</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marson</surname><given-names>A</given-names></name><name><surname>Kretschmer</surname><given-names>K</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Jacobsen</surname><given-names>ES</given-names></name><name><surname>Polansky</surname><given-names>JK</given-names></name><name><surname>Macisaac</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Foxp3 occupancy and regulation of key target genes during T-cell stimulation</article-title><source>Nature</source><year>2007</year><volume>445</volume><issue>7130</issue><fpage>931</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/nature05478</pub-id><pub-id pub-id-type="pmid">17237765</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Josefowicz</surname><given-names>SZ</given-names></name><name><surname>Kas</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>TT</given-names></name><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells</article-title><source>Nature</source><year>2007</year><volume>445</volume><issue>7130</issue><fpage>936</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nature05563</pub-id><pub-id pub-id-type="pmid">17237761</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samstein</surname><given-names>RM</given-names></name><name><surname>Arvey</surname><given-names>A</given-names></name><name><surname>Josefowicz</surname><given-names>SZ</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Reynolds</surname><given-names>A</given-names></name><name><surname>Sandstrom</surname><given-names>R</given-names></name><etal/></person-group><article-title>Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification</article-title><source>Cell</source><year>2012</year><volume>151</volume><issue>1</issue><fpage>153</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.053</pub-id><pub-id pub-id-type="pmid">23021222</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Horng</surname><given-names>T</given-names></name></person-group><article-title>Transcriptional control of the inflammatory response</article-title><source>Nat Rev Immunol</source><year>2009</year><volume>9</volume><issue>10</issue><fpage>692</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1038/nri2634</pub-id><pub-id pub-id-type="pmid">19859064</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>G</given-names></name><name><surname>Bromberg</surname><given-names>JS</given-names></name></person-group><article-title>Epigenetic mechanisms of regulation of Foxp3 expression</article-title><source>Blood</source><year>2009</year><volume>114</volume><issue>18</issue><fpage>3727</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-05-219584</pub-id><pub-id pub-id-type="pmid">19641188</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JZ</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Chen</surname><given-names>JZ</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><etal/></person-group><article-title>Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease</article-title><source>Atherosclerosis</source><year>2013</year><volume>228</volume><issue>2</issue><fpage>346</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.01.027</pub-id><pub-id pub-id-type="pmid">23566804</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettini</surname><given-names>ML</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name><name><surname>Bettini</surname><given-names>M</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Rehg</surname><given-names>JE</given-names></name><name><surname>Floess</surname><given-names>S</given-names></name><etal/></person-group><article-title>Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency</article-title><source>Immunity</source><year>2012</year><volume>36</volume><issue>5</issue><fpage>717</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.020</pub-id><pub-id pub-id-type="pmid">22579476</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeker</surname><given-names>LT</given-names></name><name><surname>Bour-Jordan</surname><given-names>H</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><article-title>Breakdown in peripheral tolerance in type 1 diabetes in mice and humans</article-title><source>Cold Spring Harbor Perspect Med</source><year>2012</year><volume>2</volume><issue>3</issue><fpage>a007807</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a007807</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Control of regulatory T cell development by the transcription factor Foxp3</article-title><source>Science</source><year>2003</year><volume>299</volume><issue>5609</issue><fpage>1057</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.1079490</pub-id><pub-id pub-id-type="pmid">12522256</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontenot</surname><given-names>JD</given-names></name><name><surname>Gavin</surname><given-names>MA</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Foxp3 programs the development and function of CD4&#x02009;+&#x02009;CD25+ regulatory T cells</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><issue>4</issue><fpage>330</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/ni904</pub-id><pub-id pub-id-type="pmid">12612578</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahedi</surname><given-names>G</given-names></name><name><surname>CP</surname><given-names>A</given-names></name><name><surname>Hand</surname><given-names>TW</given-names></name><name><surname>Laurence</surname><given-names>A</given-names></name><name><surname>Kanno</surname><given-names>Y</given-names></name><name><surname>O'Shea</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Helper T-cell identity and evolution of differential transcriptomes and epigenomes</article-title><source>Immunol Rev</source><year>2013</year><volume>252</volume><issue>1</issue><fpage>24</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/imr.12037</pub-id><pub-id pub-id-type="pmid">23405893</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The forkhead transcription factors play important roles in vascular pathology and immunology</article-title><source>Adv Exp Med Biol</source><year>2009</year><volume>665</volume><fpage>90</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-1599-3_7</pub-id><pub-id pub-id-type="pmid">20429418</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvir</surname><given-names>A</given-names></name><name><surname>Conaway</surname><given-names>JW</given-names></name><name><surname>Conaway</surname><given-names>RC</given-names></name></person-group><article-title>Mechanism of transcription initiation and promoter escape by RNA polymerase II</article-title><source>Curr Opin Genet Dev</source><year>2001</year><volume>11</volume><issue>2</issue><fpage>209</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0959-437X(00)00181-7</pub-id><pub-id pub-id-type="pmid">11250146</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Bountra</surname><given-names>C</given-names></name><name><surname>Fish</surname><given-names>PV</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name></person-group><article-title>Epigenetic protein families: a new frontier for drug discovery</article-title><source>Nat Rev Drug Discov</source><year>2012</year><volume>11</volume><issue>5</issue><fpage>384</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nrd3674</pub-id><pub-id pub-id-type="pmid">22498752</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portela</surname><given-names>A</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Epigenetic modifications and human disease</article-title><source>Nat Biotechnol</source><year>2010</year><volume>28</volume><issue>10</issue><fpage>1057</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nbt.1685</pub-id><pub-id pub-id-type="pmid">20944598</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Non-coding RNAs in human disease</article-title><source>Nat Rev Genet</source><year>2011</year><volume>12</volume><issue>12</issue><fpage>861</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nrg3074</pub-id><pub-id pub-id-type="pmid">22094949</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>KM</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Postepska</surname><given-names>A</given-names></name><name><surname>Grummt</surname><given-names>I</given-names></name></person-group><article-title>Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes</article-title><source>Genes Dev</source><year>2010</year><volume>24</volume><issue>20</issue><fpage>2264</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1101/gad.590910</pub-id><pub-id pub-id-type="pmid">20952535</pub-id></element-citation></ref></ref-list></back></article>